We've got the experience
Teva Pharmaceuticals Ltd
Our parent company, Teva Pharmaceutical Industries Ltd, develops, manufactures and markets generic and innovative human pharmaceuticals and API, as well as animal health pharmaceutical products. We are the largest generic pharmaceutical company in the world and among the top 20 of all pharmaceutical companies worldwide; over 80% of our sales occur in North America and Europe.
Teva UK Ltd
The 70-year history of Teva UK Ltd has two consistent themes: our committed focus on generics, respiratory and hospital products; and a determination to improve our abilities, our products and our services.
Previously known as APS Berk, the company's name and reputation stretch
back to the 1930s selling a range of brands and generics which has enabled us to become one of the UK's leading generics manufacturers. In 1996, APS Berk was acquired by Teva Pharmaceutical Industries Ltd. In 2006, Teva acquired the Ivax Corporation, which added a wider variety of products and new capabilities in respiratory care.
Teva is among the top 20 pharmaceutical companies in the world, and undoubtedly the largest in generic products. Our wide range of competitively priced, generic pharmaceuticals has helped us to strengthen our position as the UK's leading generics manufacturer. Teva UK Ltd is now the number one supplier of medicines to the NHS.
Teva Hospitals
The creation of Teva Hospitals brings the benefits of quality, value and innovation to the UK market. Focused on the provision of oncology injectables, infection control and solid dose pharmaceuticals, our growing portfolio is characterised by an extensive choice of product presentations and strengths. Furthermore, it is backed by high standards of customer service, including a dedicated Medical Information office in Harlow that provides readily accessible medical advice to healthcare professionals on all aspects of the Teva Hospitals' product range.
Supported by multiple international production and distribution facilities, Teva Hospitals represents a reliable and robust supply chain for the UK hospital sector. Significantly, our parent company’s approach to the generics industry is characterised by vertical integration, with ownership of every stage of the process, from the manufacture of Active Pharmaceutical Ingredients (API), right through to marketing and sales. As a result, our customers are guaranteed highly competitive pricing structures.
